The third patient in stem cell specialist ’s () early-stage clinical trial treating people with a rare eye disease will receive the therapy next week.
Researchers at Massachusetts Eye and Ear in Boston are using human retinal progenitor cells (hRPC) to possibly halt the progression of retinitis pigmentosa (RP).
Michael Hunt, chief financial officer, tells Proactive Investors “it’s important because the third patient marks the end of the first dose cohort in this particular study…so that’s good progression”.
They are carrying out a phase I/II clinical study on 15 acute sufferers of the degenerative conditions, and hunt says he expects the rest to be completed “over the course of this and possibly a little bit into next year” depending on the recruitment process.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE